Considering that diffuse-type GC-initiating cells were more resistant to anti-tumor drugs than intestinal-type cells or established GC cell lines (Additional file 1: Figure S5), these results indicate that mTOR inhibitors may be useful for the treatment of diffuse-type GC-initiating cells. This evidence concerns the gene MTOR and gastric cancer.